Effect of Resveratrol on Treg/Th17 Signaling and Ulcerative Colitis Treatment in Mice

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Jun 16

PMID 26074695

Citations 43

Authors

Jun Yao

Cheng Wei

Jian-Yao Wang

Ru Zhang

Ying-Xue Li

Li-Sheng Wang

Affiliations

Soon will be listed here.

Abstract

Aim: To determine the therapeutic efficacy of resveratrol on ulcerative colitis (UC) and its underlying mechanisms.

Methods: The mouse UC model was developed using 5% dextran sulfate sodium. Mice were randomly divided into four groups: normal control, UC model group, resveratrol low-dose group (RLD; 50 mg/kg per day), and resveratrol high-dose group (RHD; 100 mg/kg per day).

Results: The results showed that RLD regulates Treg/Th17 balance mainly through reducing the number of Th17 cells, whereas RHD regulates Treg/Th17 balance through both downregulating the number of Th17 cells and upregulating the number of Treg cells. Resveratrol can also regulate the level of plasma and intestinal mucosal cytokines including interleukin (IL)-10, transforming growth factor-β1, IL-6, and IL-17. The expressions of hypoxia inducible factor (HIF)-1α, mammalian target of rapamycin (mTOR), and signal transducer and activator of transcription 3 were significantly decreased in the intestinal tissues of mice treated with resveratrol.

Conclusion: The therapeutic efficacy of resveratrol in UC is dose dependent and closely associated with the regulation of Treg/Th17 balance and the HIF-1α/mTOR signaling pathway.

Citing Articles

Down-regulation of interlinked inflammatory signalling cascades by ethanolic extract of Suaeda fruticosa Forssk. ex J.F. Gmel. attenuated in vivo inflammatory and nociceptive responses.

Fiaz M, Elsadek M, Al-Numair K, Chaudhry S, Saleem M, Khan K Inflammopharmacology. 2024; 33(1):311-328.

PMID: 39731702 DOI: 10.1007/s10787-024-01624-7.

: An Important Model for Exploring the Pathways of Inflammatory Bowel Disease (IBD) in the Intestinal Tract.

Zeng C, Liu F, Huang Y, Liang Q, He X, Li L Int J Mol Sci. 2024; 25(23).

PMID: 39684456 PMC: 11641265. DOI: 10.3390/ijms252312742.

Harnessing the Anti-Inflammatory Properties of Polyphenols in the Treatment of Inflammatory Bowel Disease.

Boaru D, Fraile-Martinez O, De Leon-Oliva D, Garcia-Montero C, De Castro-Martinez P, Miranda-Gonzalez A Int J Biol Sci. 2024; 20(14):5608-5672.

PMID: 39494333 PMC: 11528451. DOI: 10.7150/ijbs.98107.

Effects of Pine Pollen Polysaccharides and Sulfated Polysaccharides on Ulcerative Colitis in Mice by Regulating Th17/Treg.

Wang Z, Li Z, Wang H, Wu Q, Geng Y Foods. 2024; 13(19).

PMID: 39410218 PMC: 11475350. DOI: 10.3390/foods13193183.

Lactic Acid Bacteria-Gut-Microbiota-Mediated Intervention towards Inflammatory Bowel Disease.

Li D, Liu Z, Fan X, Zhao T, Wen D, Huang X Microorganisms. 2024; 12(9).

PMID: 39338538 PMC: 11433943. DOI: 10.3390/microorganisms12091864.

References

Ardizzone S, Porro G . Biologic therapy for inflammatory bowel disease. Drugs. 2005; 65(16):2253-86. DOI: 10.2165/00003495-200565160-00002. View

Gupta S . Immune homeostasis: regulatory T cells (Treg) and molecules. J Clin Immunol. 2008; 28(6):617-8. DOI: 10.1007/s10875-008-9259-3. View

Reddy J, Loftus Jr E . Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006; 35(4):837-55. DOI: 10.1016/j.gtc.2006.09.008. View

Abdallah D, Ismael N . Resveratrol abrogates adhesion molecules and protects against TNBS-induced ulcerative colitis in rats. Can J Physiol Pharmacol. 2011; 89(11):811-8. DOI: 10.1139/y11-080. View

Lichtenstein G, Rutgeerts P . Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009; 16(2):338-46. DOI: 10.1002/ibd.20997. View

Stephani J, Radulovic K, Hendrik Niess J . Gut microbiota, probiotics and inflammatory bowel disease. Arch Immunol Ther Exp (Warsz). 2011; 59(3):161-77. DOI: 10.1007/s00005-011-0122-5. View

Kleczynska W, Jakiela B, Plutecka H, Milewski M, Sanak M, Musial J . Imbalance between Th17 and regulatory T-cells in systemic lupus erythematosus. Folia Histochem Cytobiol. 2012; 49(4):646-53. DOI: 10.5603/fhc.2011.0088. View

Feagan B, Reinisch W, Rutgeerts P, Sandborn W, Yan S, Eisenberg D . The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007; 102(4):794-802. DOI: 10.1111/j.1572-0241.2007.01094.x. View

Abraham C, Cho J . Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15(7):1090-100. DOI: 10.1002/ibd.20894. View

10.

Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H . Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res. 2007; 27(6A):3749-56. View

11.

Scharl M, Rogler G . Inflammatory bowel disease pathogenesis: what is new?. Curr Opin Gastroenterol. 2012; 28(4):301-9. DOI: 10.1097/MOG.0b013e328353e61e. View

12.

Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf J . Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis. 2010; 13(4):305-15. PMC: 2980626. DOI: 10.1007/s10456-010-9187-8. View

13.

Unutmaz D, Pulendran B . The gut feeling of Treg cells: IL-10 is the silver lining during colitis. Nat Immunol. 2009; 10(11):1141-3. DOI: 10.1038/ni1109-1141. View

14.

Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R . CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci. 2010; 56(2):376-86. DOI: 10.1007/s10620-010-1286-2. View

15.

Nutsch K, Hsieh C . When T cells run out of breath: the HIF-1α story. Cell. 2011; 146(5):673-4. DOI: 10.1016/j.cell.2011.08.018. View

16.

Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T . Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008; 58(4):1197-200. DOI: 10.1002/art.23373. View

17.

Sands B . Therapy of inflammatory bowel disease. Gastroenterology. 2000; 118(2 Suppl 1):S68-82. DOI: 10.1016/s0016-5085(00)70007-2. View

18.

Liu Z, Yadav P, Su J, Wang J, Fei K . Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2009; 15(46):5784-8. PMC: 2791270. DOI: 10.3748/wjg.15.5784. View

19.

Lohr J, Knoechel B, Caretto D, Abbas A . Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect. 2009; 11(5):589-93. PMC: 2720614. DOI: 10.1016/j.micinf.2009.04.012. View

20.

Hundorfean G, Neurath M, Mudter J . Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis. 2011; 18(1):180-6. DOI: 10.1002/ibd.21677. View